Fibrotic diseases cause harmful scar tissue in skin and organs. Researchers at Yale made a human monoclonal antibody that targets epiregulin, a molecule that binds the epidermal growth factor receptor (EGFR). Earlier work showed epiregulin was higher in skin from people with scleroderma.
The team compared single-cell RNA data from scleroderma and fibrotic graft-versus-host disease and found epiregulin was upregulated. They tested the antibody in humanized mice and in patient skin biopsies. Inhibiting epiregulin reduced biomarkers linked to fibrosis. A separate study showed more STAT1 activity in fibroblasts from fibrotic diseases. The researchers plan to test the therapy in lupus and hidradenitis suppurativa.
Difficult words
- researcher — A person who studies something carefully.Researchers
- treat — To help someone become healthy or better.treating
- disease — An illness that affects the body.diseases
- therapy — A treatment to help someone feel better.
- molecule — A very small part of a substance.
- scarring — The marks left on skin after an injury.
- fibrosis — A condition where thick tissue forms in the body.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- What do you think about the importance of research in medicine?
- How might antibody therapy change treatments for diseases?
- Why is it important to develop better treatments for fibrotic diseases?
Related articles
Study: Year‑round RSV Immunization Could Reduce Big Outbreaks
A study in Science Advances finds that offering RSV immunizations year‑round would lower the chance of large seasonal outbreaks in the United States. Researchers compared spread in cities and rural areas and tested seasonal versus year‑round schedules.
